Claims in this piece are observable and methodological — no client or benchmark data used.
A buyer looking for a CDMO does not necessarily arrive at your website because they already know your company.
They may arrive after asking an AI assistant which manufacturers can handle sterile fill-finish for a regulated market. They may have been given several names and are now checking whether the companies actually appear capable of doing the work.
That changes the job of the website.
For years, pharmaceutical websites were largely treated as corporate brochures: establish credibility, describe the company, list capabilities, display certifications, provide contact details and give the commercial team something to point prospects towards.
That model still has value. But it misses what happens before the enquiry.
Today, your website can be part of the evidence an outsider uses to decide whether your company belongs on a shortlist in the first place.
The distinction is subtle but commercially important: a brochure tells people about your company; a commercially useful website gives an outsider enough specific evidence to understand it. For a CDMO, those are not the same thing.
What has changed about the website’s job?
The website now has to work for at least two audiences at the same time.
The first is the conventional human visitor: a procurement lead, technical evaluator, BD professional or prospective client who is actively reading your pages.
The second is the intermediary doing the early research: an AI assistant interpreting your public information and attempting to answer a buyer’s question.
The second audience does not read your website in the same way a human does. It needs to establish things such as: what does this manufacturer actually make? Which dosage forms or technologies does it specialise in? Which markets and regulatory environments does it serve? What therapeutic or technical depth does it have? Which facts can be stated confidently rather than inferred? Does the information agree with what appears elsewhere?
That is why phrases such as “integrated solutions,” “world-class facilities” and “end-to-end capabilities” are weak commercial evidence on their own. They may sound reassuring to someone who already knows the company. They do very little to distinguish one manufacturer from another. Compare:
with:
“We manufacture oral solid dosage tablets and capsules for regulated export markets, with dedicated capabilities for modified-release formulations.”
The second statement gives an evaluator something to work with. It may still need verification. It may not answer every buyer question. But it is specific enough to be understood. That is the standard your website increasingly has to meet.
What should a pharmaceutical website make clear?
The answer does not require a new marketing framework. It is the same four confirmations described in Emerivo’s research on why some manufacturers are shortlisted before the first sales call: capability fit, regulatory credibility, demonstrated depth and coherence. The website’s job is to make those confirmations easy to establish from public information.
1. Capability fit
A buyer should not have to interpret your website to work out whether you can make the product they need. If you manufacture sterile injectables, say so. If you have lyophilisation capability, state it. If you handle HPAPI, explain the relevant capability accurately. If your strength is oral solid dosage, distinguish the forms and technologies you genuinely handle. The more specific the requirement, the less useful generic category language becomes.
2. Regulatory credibility
Regulatory standing should be stated precisely enough that an outsider can understand what it means. “Globally compliant” is not a useful substitute for naming the relevant approval, certification or market context. A buyer investigating an EU-GMP manufacturing partner and a buyer looking for a US FDA-regulated supplier are asking different questions. The website should make the relevant facts discoverable rather than forcing the evaluator to reconstruct them from brochures, logos and assumptions.
3. Demonstrated depth
Capability is not the same as expertise. A manufacturer may technically offer biologics, oncology manufacturing or technology transfer without giving an outsider much reason to believe there is meaningful depth behind the claim. This is where process matters. Describe the relevant development or manufacturing experience, technology-transfer capability, containment approach, facilities or other genuine differentiators where those details can be stated accurately. A page full of adjectives is not evidence of depth.
4. Coherence
This is the one companies often underestimate. Your website may say one thing. A corporate profile elsewhere may describe a different capability set. An old directory entry may use outdated terminology. A facility page may give a different location or manufacturing scope. A human buyer can ask you to explain the discrepancy. An AI assistant may simply produce a less confident or incomplete account. The website therefore cannot be treated in isolation. It has to form part of a coherent public record.
What does this mean for a CDMO website in practice?
It does not mean turning every page into an SEO exercise. Nor does it mean writing for machines instead of people. It means removing the unnecessary burden placed on an outsider trying to understand your business. A practical review should ask:
If the answer is no, the problem is not necessarily your capability. It may be the way that capability is represented. That distinction matters commercially. A CDMO might have an excellent sterile facility, experienced technical-transfer personnel and the right regulatory approvals, yet present all three behind a generic homepage, a capability PDF and a paragraph about “quality and innovation.” The underlying business has not changed. The information available to the outside evaluator has.
The website should support the buyer’s actual questions
This is where many pharmaceutical websites become internally focused. They organise information according to the company’s structure: About us. Our facilities. Our services. Our values. Our quality.
A buyer thinks differently. They may be asking: “Which CDMOs can handle sterile injectable technology transfer for an EU-regulated programme?” Or: “Which manufacturers have experience with high-potency oral solid dosage products?” Or: “Can this organisation manufacture the dosage form we need and support the relevant market?”
Those questions should determine whether the necessary evidence is actually present and connected across the site.
This is also where AI Visibility becomes relevant. AI Visibility is not about making a website sound as though it was written for an AI model. It is about making genuine company facts sufficiently clear, specific and consistent that an AI assistant — as well as a human buyer — can understand them.
Emerivo helps pharmaceutical manufacturers and research organisations — TPMs, CMOs, CDMOs and CROs — address this through its AI Discovery Audit™, which tests how ChatGPT, Gemini, Perplexity, Claude and Copilot currently understand an organisation against realistic buyer questions. The audit is diagnostic; it does not guarantee recommendation or ranking.
A simple demonstration you can run yourself
Take one capability that matters commercially. For example: your company is a CDMO for sterile injectables.
Now ask ChatGPT: “What can you tell me about [Company] as a CDMO for sterile injectables? What dosage forms, regulatory markets, manufacturing capabilities and relevant specialisations can you establish from public information?”
Then repeat the same question in Gemini, Perplexity, Claude and Copilot.
Do not treat the responses as proof of your market position. Instead, compare them with your own website. Can each platform establish the same basic facts? Where are the answers vague? Which genuine capabilities are missing? Are any facts incorrect? Does the answer confuse development capability with manufacturing capability? Does one platform describe you substantially differently from another?
That is a reproducible observation exercise, not a ranking test. And it can reveal something a conventional website analytics dashboard cannot: what an outside system can actually establish about your company before your commercial team enters the conversation.
If our website were the only briefing document a stranger had before deciding whether to investigate us, would it make the right case for the business we actually run?
That is a more useful question than “does our website look professional?” Professional appearance matters. But appearance is not the same as commercial legibility.
Your website is now part of the commercial process
The strongest pharmaceutical websites will not necessarily be the ones with the most pages, the most animation or the most polished corporate language. They will be the ones that make the underlying business unusually easy to understand.
A buyer should be able to establish what you make, where your genuine depth lies, which regulatory context applies and whether the overall story is coherent — without needing someone from your organisation to translate the website for them. That is not a technology trick. It is good commercial communication applied to a different stage of the buying process.
And if you want to know what AI assistants can currently establish about your organisation, the AI Discovery Audit™ is the practical starting point. Emerivo tests your company against real buyer questions, identifies where AI is accurate, vague, incorrect or unable to find you, and turns those observations into an actionable improvement plan. For the broader buyer behaviour behind this shift, read Why Some Pharmaceutical Manufacturers Are Shortlisted Before the First Sales Call and The Questions Buyers Ask Before They Shortlist You — And How to Be Ready.
Frequently asked questions
No. The objective is clear, accurate information that works for both. Specific capability statements, regulatory facts and consistent corporate information are useful to human buyers as well as AI systems.
No. The relevant question is whether an outsider can establish the facts needed to understand your genuine capabilities and suitability. Sensitive or controlled information should remain appropriately restricted.
No. No credible organisation can guarantee AI recommendations. Improving the clarity and consistency of genuine information can make a company easier to understand, but recommendation behaviour remains outside a supplier’s control.
No. SEO focuses primarily on visibility within search engines and search results. AI Visibility concerns whether AI assistants can find, interpret and accurately represent an organisation when a buyer asks a relevant question. The two can overlap, but they are not identical.